Jason Haney: No financial relationships to disclose
Pharmacists are valuable members of the multidisciplinary team approach to long-term management of heart failure (HF) and its health-related impacts with the goals of improving patient quality of life and preventing death. This activity will explore the updated universal definition of HF, including revised staging as well as new and revised classifications of HF according to left ventricular ejection fraction. Newly approved and emerging therapies for the treatment of chronic or worsening HF will be reviewed to assist pharmacists with clinical decision making for the initiation, titration, and monitoring of HF therapies for patients.
Compare and contrast the classifications and stages of HF.
Apply therapeutic principles from the new AHA/ACC/HFSA heart failure guidelines, including initiation and titration of guideline-directed medical therapies (GDMT), to patient-specific scenarios.
Describe when and how additional medical therapies (beyond the core four GDMT) should be integrated into the management of HF with reduced EF (HFrEF).
Explain practical strategies to mitigate potential barriers to GDMT initiation.
Discuss strategies to optimize transitions of care from inpatient to outpatient care to reduce hospital admissions.